DDrare: Database of Drug Development for Rare Diseases

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	993

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

trials per page:

Showing 1 to 10 of 993 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05504187 (ClinicalTrials.gov)	October 2023	15/8/2022	Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic ...	An Open-label, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic ...	Systemic Lupus Erythematosus	Drug: KP104	Kira Pharmacenticals (US), LLC.	NULL	Not yet recruiting	18 Years	65 Years	All	24	Phase 2	NULL
2	NCT05029336 (ClinicalTrials.gov)	September 2023	24/8/2021	Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases	Autologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Au ...	Systemic Lupus Erythematosus;Systemic Sclerosis	Biological: Depletion of CD3/CD19 in an autologous stem cell transplant	Stephan Grupp MD PhD	NULL	Recruiting	8 Years	25 Years	All	20	Phase 2	United States
3	NCT04893161 (ClinicalTrials.gov)	June 1, 2023	16/5/2021	A Model About the Response of Belimumab in SLE	A Model to Early Predict the Response of Belimumab Treatment in the Patients With Systemic Lupus Ery ...	Systemic Lupus Erythematosus	Drug: Belimumab	First Affiliated Hospital Xi'an Jiaotong University	NULL	Not yet recruiting	18 Years	N/A	All	72	Phase 4	NULL
4	NCT05688696 (ClinicalTrials.gov)	March 31, 2023	10/1/2023	Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosu ...	A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficac ...	Systemic Lupus Erythematosus, SLE	Drug: Orelabrutinib (Low Dose);Drug: Orelabrutinib (High Dose);Drug: Orelabrutinib Placebo	Beijing InnoCare Pharma Tech Co., Ltd.	NULL	Not yet recruiting	18 Years	75 Years	All	186	Phase 2	China
5	NCT05440422 (ClinicalTrials.gov)	March 22, 2023	29/6/2022	The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythe ...	The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythe ...	Systemic Lupus Erythematosus;Cardiovascular Disease;Premature Atherosclerosis	Drug: anifrolumab;Other: Placebo	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	NULL	Not yet recruiting	18 Years	80 Years	All	45	Phase 1	United States
6	NCT05624749 (ClinicalTrials.gov)	March 7, 2023	7/11/2022	Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lup ...	A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safet ...	Systemic Lupus Erythematosus	Drug: ianalumab;Drug: placebo	Novartis Pharmaceuticals	NULL	Not yet recruiting	12 Years	N/A	All	280	Phase 3	NULL
7	NCT05639114 (ClinicalTrials.gov)	March 1, 2023	4/11/2022	Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients W ...	A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate ...	Systemic Lupus Erythematosus	Drug: Ianalumab;Drug: Placebo	Novartis Pharmaceuticals	NULL	Not yet recruiting	12 Years	N/A	All	406	Phase 3	NULL
8	NCT05638802 (ClinicalTrials.gov)	March 2023	28/11/2022	A Study of DS-7011a in Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus	A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety ...	Systemic Lupus Erythematosus;Cutaneous Lupus Erythematosus	Drug: DS-7011a;Drug: Placebo	Daiichi Sankyo, Inc.	NULL	Not yet recruiting	18 Years	N/A	All	24	Phase 1/Phase 2	NULL
9	NCT05765006 (ClinicalTrials.gov)	February 24, 2023	6/2/2023	CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus	A Phase I Dose-escalation Study Evaluate the Safety Tolerability Pharmacokinetics(PK) and Pharmacody ...	Systemic Lupus Erythematosus	Biological: Relma-cel	Shanghai Ming Ju Biotechnology Co., Ltd.	NULL	Recruiting	18 Years	70 Years	All	24	Phase 1	China
10	EUCTR2022-002691-36-SK (EUCTR)	07/02/2023	24/10/2022	Phase 3 study to evaluate two regimens of ianalumab on top of standard-of-care therapy in patients w ...	A randomized, double-blind, parallel group, placebo-controlled multicenter phase 3 study to evaluate ...	Systemic Lupus Erythematosus <br>MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: S ...	Product Name: ianalumab<br>Product Code: VAY736<br>INN or Proposed INN: IANALUMAB<br>Other descripti ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes<br>Male: yes	406	Phase 3	Hungary;United States;Czechia;Japan;Thailand;Portugal;Spain;Canada;Czech Republic;Turkey;China;Brazi ...

First Previous1 2 3 4 5…100Next Last